Loading…
Loading…
EQUITY / NASDAQ · XNCM
Inhibikase Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 2 USD · Volume 434,460
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 0 USD | 0 USD | — |
| Operating profit | -21,050,995 USD | -10,832,278 USD | — |
| Net income | -19,591,231 USD | -9,915,523 USD | — |
| Total liabilities | 10,260,026 USD | — | — |
| Total equity | 153,328,586 USD | 80,053,685 USD | +91.53% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -19,591,231 USD | -35,972,071 USD | -16,380,840 USD | — | -48,259,189 USD | -11,930,280 USD | -35,524,538 USD | -9,915,523 USD |
| Operating profitIncome statement | -21,050,995 USD | -38,892,914 USD | — | — | -51,974,283 USD | -12,768,373 USD | -38,198,657 USD | -10,832,278 USD |
| RevenueIncome statement | 0 USD | 0 USD | — | — | — | 0 USD | 0 USD | 0 USD |
| Total assetsBalance sheet | 163,588,612 USD | — | — | 181,204,516 USD | 181,204,516 USD | 79,594,541 USD | — | — |
| Total equityBalance sheet | 153,328,586 USD | — | 167,620,268 USD | 172,903,679 USD | 172,903,679 USD | 72,898,298 USD | — | 80,053,685 USD |
| Total liabilitiesBalance sheet | 10,260,026 USD | — | — | 8,300,837 USD | 8,300,837 USD | 6,696,243 USD | — | — |
| Capital expendituresCash flow statement | — | 0 USD | — | — | 13,399 USD | — | 13,399 USD | — |
| Financing cash flowCash flow statement | — | 2,883,122 USD | — | — | 108,462,963 USD | — | -102,359 USD | — |
| Investing cash flowCash flow statement | — | -86,393,289 USD | — | — | 2,053,130 USD | — | 2,151,977 USD | — |
| Operating cash flowCash flow statement | — | -24,503,334 USD | — | — | -27,786,464 USD | — | -20,270,491 USD | — |
| Cash and cash equivalentsBalance sheet | — | — | — | — | 178,800,000 USD | — | — | — |
| Report source | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 03/26/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/11/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.